Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Giantonio

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Problems in Cancer|November 1, 1994
Prostate cancerW R Lee, B Giantonio, G E Hanks
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Genitourinary malignancyB Giantonio, R F Ozols, G R Hudes
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Genitourinary malignancyG R Hudes, R F Ozols, B Giantonio
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Genitourinary malignancyJ Leighton, J Clark, B Giantonio, et al.
Seminars in Oncology|April 1, 1997
Adjuvant chemotherapy for breast cancer in pregnancy: can recommendations be made with confidenceJ Stevenson, B Giantonio, R L Boyd, et al.
British Journal of Cancer|May 5, 2005
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancerM L Veronese, W Sun, B Giantonio, et al.
Cancer|July 24, 2001
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumorsW Sun, J P Stevenson, M Gallagher, et al.
The Journal of Urology|August 8, 2001
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomyE T Goluboff, D Prager, D Rukstalis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancerJ P Stevenson, M Redlinger, L A Kluijtmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancerG R Hudes, F Nathan, C Khater, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Problems in Cancer|November 1, 1994
Prostate cancerW R Lee, B Giantonio, G E Hanks
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Genitourinary malignancyB Giantonio, R F Ozols, G R Hudes
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Genitourinary malignancyG R Hudes, R F Ozols, B Giantonio
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Genitourinary malignancyJ Leighton, J Clark, B Giantonio, et al.
Seminars in Oncology|April 1, 1997
Adjuvant chemotherapy for breast cancer in pregnancy: can recommendations be made with confidenceJ Stevenson, B Giantonio, R L Boyd, et al.
British Journal of Cancer|May 5, 2005
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancerM L Veronese, W Sun, B Giantonio, et al.
Cancer|July 24, 2001
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumorsW Sun, J P Stevenson, M Gallagher, et al.
The Journal of Urology|August 8, 2001
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomyE T Goluboff, D Prager, D Rukstalis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancerJ P Stevenson, M Redlinger, L A Kluijtmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancerG R Hudes, F Nathan, C Khater, et al.
Pageof 2